Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Viemed Healthcare (VMD) EBITDA (2018 - 2026)

Viemed Healthcare filings provide 8 years of EBITDA readings, the most recent being $8.4 million for Q4 2025.

  • On a quarterly basis, EBITDA rose 29.74% to $8.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $22.9 million, a 32.66% increase, with the full-year FY2025 number at $22.9 million, up 103.72% from a year prior.
  • EBITDA hit $8.4 million in Q4 2025 for Viemed Healthcare, up from $5.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $8.4 million in Q4 2025 to a low of $1.0 million in Q2 2022.
  • Median EBITDA over the past 5 years was $2.7 million (2022), compared with a mean of $3.3 million.
  • Biggest five-year swings in EBITDA: crashed 91.95% in 2021 and later skyrocketed 150.13% in 2023.
  • Viemed Healthcare's EBITDA stood at $4.1 million in 2021, then tumbled by 42.45% to $2.4 million in 2022, then skyrocketed by 45.97% to $3.5 million in 2023, then skyrocketed by 85.56% to $6.5 million in 2024, then increased by 29.74% to $8.4 million in 2025.
  • The last three reported values for EBITDA were $8.4 million (Q4 2025), $5.6 million (Q3 2025), and $5.1 million (Q2 2025) per Business Quant data.